Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670215 · ClinicalTrials.gov registry record · Phase 3
BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 497
- Enrollment target
NCT00670215: Completed Phase 3 study, sponsored by Bayer.
NCT00670215 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 497 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670215, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 497 participants
- Enrollment target
Study Summary
The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biopsies of the prostate (TRNBP).
Interventions
- DRUG Ciprofloxacin single dose
- DRUG Ciprofloxacin triple dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
What the finished NCT00670215 record still lists
NCT00670215 is an interventional study that assigns participants to a tested intervention. The registered 497 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which Ciprofloxacin single dose is the first listed.
NCT00670215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00670215 about?
NCT00670215 is a clinical study titled "BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis". The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biops...
What is the current status of trial NCT00670215?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 497 participants. The study started on 2004-04. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00670215?
The interventions under investigation include: Ciprofloxacin single dose (DRUG), Ciprofloxacin triple dose (DRUG).
Who is sponsoring clinical trial NCT00670215?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00670215's enrollment target sits among peer trials
497 775th of 2000 higher than 1,225 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
- NCT05766670 · 497 participants · Phase 3
Intramedullary Calcium Sulfate Antibiotic Depot
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia